Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lalitha K Shankar; Heiko Schöder; Elad Sharon; Jedd Wolchok; Michael V Knopp; Richard L Wahl; Benjamin M Ellingson; Nathan C Hall; Martin J Yaffe; Alexander J Towbin; Michael D Farwell; Daniel Pryma; Tina Young Poussaint; Chadwick L Wright; Lawrence Schwartz; Mukesh Harisinghani; Umar Mahmood; Anna M Wu; David Leung; Elisabeth G E de Vries; Ying Tang; Gillian Beach; Steven A Reeves

doi:10.1016/S1470-2045(22)00742-2

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lalitha K Shankar^*, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V Knopp, Richard L Wahl, Benjamin M Ellingson, Nathan C Hall, Martin J Yaffe, Alexander J Towbin, Michael D Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M Wu, David Leung, Elisabeth G E de VriesYing Tang, Gillian Beach, Steven A Reeves

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

310 Downloads (Pure)

Abstract

As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

Original language	English
Pages (from-to)	e133-e143
Number of pages	11
Journal	Lancet Oncology
Volume	24
Issue number	3
Early online date	27-Feb-2023
DOIs	https://doi.org/10.1016/S1470-2045(22)00742-2
Publication status	Published - Mar-2023

Keywords

United States
Humans
National Cancer Institute (U.S.)
Neoplasms
Immunotherapy
Image Processing, Computer-Assisted
Medical Oncology

Access to Document

10.1016/S1470-2045(22)00742-2

Harnessing imaging tools to guide immunotherapy trialsFinal publisher's version, 248 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Shankar, L. K., Schöder, H., Sharon, E., Wolchok, J., Knopp, M. V., Wahl, R. L., Ellingson, B. M., Hall, N. C., Yaffe, M. J., Towbin, A. J., Farwell, M. D., Pryma, D., Poussaint, T. Y., Wright, C. L., Schwartz, L., Harisinghani, M., Mahmood, U., Wu, A. M., Leung, D., ... Reeves, S. A. (2023). Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. Lancet Oncology, 24(3), e133-e143. https://doi.org/10.1016/S1470-2045(22)00742-2

@article{7cdde5d043334c3990e8dd30fe3361ee,

title = "Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop",

abstract = "As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.",

keywords = "United States, Humans, National Cancer Institute (U.S.), Neoplasms, Immunotherapy, Image Processing, Computer-Assisted, Medical Oncology",

author = "Shankar, {Lalitha K} and Heiko Sch{\"o}der and Elad Sharon and Jedd Wolchok and Knopp, {Michael V} and Wahl, {Richard L} and Ellingson, {Benjamin M} and Hall, {Nathan C} and Yaffe, {Martin J} and Towbin, {Alexander J} and Farwell, {Michael D} and Daniel Pryma and Poussaint, {Tina Young} and Wright, {Chadwick L} and Lawrence Schwartz and Mukesh Harisinghani and Umar Mahmood and Wu, {Anna M} and David Leung and {de Vries}, {Elisabeth G E} and Ying Tang and Gillian Beach and Reeves, {Steven A}",

note = "Funding Information: LKS, ES, and SAR are employed by NCI at NIH. The NCI Cancer Imaging Steering Committee workshop received no funding. The Clinical Imaging Steering Committee is operated and supported by the NCI Coordinating Center for Clinical Trials. Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = mar,

doi = "10.1016/S1470-2045(22)00742-2",

language = "English",

volume = "24",

pages = "e133--e143",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "ELSEVIER SCIENCE INC",

number = "3",

}

Shankar, LK, Schöder, H, Sharon, E, Wolchok, J, Knopp, MV, Wahl, RL, Ellingson, BM, Hall, NC, Yaffe, MJ, Towbin, AJ, Farwell, MD, Pryma, D, Poussaint, TY, Wright, CL, Schwartz, L, Harisinghani, M, Mahmood, U, Wu, AM, Leung, D, de Vries, EGE, Tang, Y, Beach, G & Reeves, SA 2023, 'Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop', Lancet Oncology, vol. 24, no. 3, pp. e133-e143. https://doi.org/10.1016/S1470-2045(22)00742-2

TY - JOUR

T1 - Harnessing imaging tools to guide immunotherapy trials

T2 - summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

AU - Shankar, Lalitha K

AU - Schöder, Heiko

AU - Sharon, Elad

AU - Wolchok, Jedd

AU - Knopp, Michael V

AU - Wahl, Richard L

AU - Ellingson, Benjamin M

AU - Hall, Nathan C

AU - Yaffe, Martin J

AU - Towbin, Alexander J

AU - Farwell, Michael D

AU - Pryma, Daniel

AU - Poussaint, Tina Young

AU - Wright, Chadwick L

AU - Schwartz, Lawrence

AU - Harisinghani, Mukesh

AU - Mahmood, Umar

AU - Wu, Anna M

AU - Leung, David

AU - de Vries, Elisabeth G E

AU - Tang, Ying

AU - Beach, Gillian

AU - Reeves, Steven A

N1 - Funding Information: LKS, ES, and SAR are employed by NCI at NIH. The NCI Cancer Imaging Steering Committee workshop received no funding. The Clinical Imaging Steering Committee is operated and supported by the NCI Coordinating Center for Clinical Trials. Publisher Copyright: © 2023 Elsevier Ltd

PY - 2023/3

Y1 - 2023/3

N2 - As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

AB - As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

KW - United States

KW - Humans

KW - National Cancer Institute (U.S.)

KW - Neoplasms

KW - Immunotherapy

KW - Image Processing, Computer-Assisted

KW - Medical Oncology

U2 - 10.1016/S1470-2045(22)00742-2

DO - 10.1016/S1470-2045(22)00742-2

M3 - Review article

C2 - 36858729

SN - 1470-2045

VL - 24

SP - e133-e143

JO - Lancet Oncology

JF - Lancet Oncology

IS - 3

ER -

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this